Harnessing bacteriocins for biotech and health
Syngulon is a synthetic biology startup developing bacteriocin-based technologies for biomanufacturing and health.
We harness bacteriocins, naturally occurring antimicrobial peptides, and their immunity systems to create innovative solutions in three areas:
-
- antibiotic-free selection for microbial production,
- precision control of microbial contamination,
- targeted antimicrobial therapies.
Industry validation
In March 2026, we announced a non-exclusive licensing agreement with Elanco Animal Health, a global leader in animal health, granting worldwide access to our proprietary bacteriocin-based microbial selection technologies.
Our technologies are designed to complement existing industrial and pharmaceutical platforms and are available to partners through non-exclusive licensing.
Through its “Startup in the Labs” model, Syngulon combines its technology portfolio with close collaborations with academic laboratories and industrial partners worldwide.
Our ambition is simple: to turn the natural precision of bacteriocins into practical technologies for biotechnology and health.
Bacteriocins
Bacteriocins are ribosomally produced, genetically encoded antimicrobial peptides made by a wide variety of bacteria. Their high specificity and diversity offer unique opportunities for biotechnology and health.
Synthetic biology makes it possible to engineer bacteriocins and their immunity systems, modify their spectrum of activity and design new functionalities. These properties form the scientific foundation of Syngulon’s technologies.
Syngulon is building PARAGEN, a collection of natural and synthetic bacteriocins that supports the development of our technologies and new applications.
+
Technologies
We harness the unique properties of bacteriocins to engineer innovative genetic technologies that address some of the most pressing challenges in biotechnology and health.
Our technology portfolio is structured around three core applications:
01
Syngulon’s patented bacteriocin-based selection technology eliminates the need for antibiotic-resistance markers in E. coli production. Fully plasmid-based and compatible with existing production workflows, it provides continuous biological selection to support stable plasmid maintenance for recombinant proteins, pDNA and other microbial bioproducts without the need of chromosomal modification.
02
Syngulon develops bacteriocin-based solutions to prevent and control microbial contamination in industrial bioprocesses. By exploiting the natural specificity of bacteriocins, these approaches can selectively target unwanted microorganisms while preserving the production organism, offering a precision alternative to conventional antimicrobial treatments.
03
Syngulon develops natural and engineered bacteriocins, including synergistic bacteriocin cocktails, as precision antimicrobials for therapeutic applications. Their targeted activity and diversity offer opportunities to address difficult-to-treat bacterial infections, including pathogens with antimicrobial resistance, while enabling the design of new bacteriocin-based therapeutic strategies.